Anti-CD7 monoclonal antibody-PAP conjugate

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD7 monoclonal antibody-PAP conjugate

Drug Alias NameAnti-CD7 pokeweed antiviral protein immunotoxinAnti-CD7 pokeweed antiviral protein immunoconjugateTXU-PAPTXU pokeweed antiviral proteinAnti-CD7 pokeweed antiviral protein

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionT-cell antigen CD7 inhibitors

TargetsT-cell antigen CD7

Therapy Area/IndicationsLymphomaLeukemia, Myeloid, AcuteHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesWayne Hughes Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesWayne Hughes Institute

Active IndicationsN/A

Inactive IndicationsLymphomaLeukemia, Myeloid, AcuteHIV Infections

Other Information

ATC CodeN/A